Norway-based Zelluna Therapeutics has named Miguel Forte as its new chief executive officer, it was reported yesterday.

In the new role, it is intended that Forte will lead the company through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.

Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, Bristol-Myers Squibb, Abbott, and UCB amongst others. His expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and he is currently chief commercialisation officer and chair of the commercialisation committee for the International Society of Cellular Therapy.